IFW



PATENT

Attorney Docket No.: A-72186/TAL/DCF

Attorney File No.: 471702-00005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

QI et al.

Serial No. 10/804,762

Filing Date: March 19, 2004

For: Specific Inhibition of Allorejection

Examiner: Not Yet Assigned

Art Unit: 1642

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

Dated:	July 19, 2004	
Signed:	# The state of the	
· —	Brent Youehara	

INFORMATION DISCLOSURE STATEMENT AND STATEMENT OF RELATEDNESS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1273 Off. Gaz. Pat. Off. 1, 8/5/2003, no copies of U.S. patents and U.S. published applications are enclosed.

Further, in satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and as required by M.P.E.P. § 2001.06(b), Applicant notes that the present application is related to the following pending patent applications:

1. U.S.S.N. 10/804,763, filed March 19, 2004.

Serial No. 10/804,762

Filing Date: March 19, 2004

None of the foregoing references are believed to disclose the invention as claimed. Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required. While no fee is believed to be due, if this belief is in error the Commissioner is authorized to charge any additional fees, including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 471702-00005 [A-72186/TAL/DCF]).

Respectfully submitted,

DORSEY & WHITNEY LLP

David C. Foster, Reg. No. 44,685 for

Todd A. Lorenz, Reg. No. 39,754

Customer Number: 32940

Dorsey & Whitney LLP

Four Embarcadero Center, Suite 3400

San Francisco, CA 94111-4187 Telephone:

(415) 781-1989

Facsimile:

(415) 398-3249

Attachments: Form PTO/SB/8A, Substitute for form 1449

12 cited references Return Postcard

By:

Substitute PTO/SB/08A (08-03) U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE. JUL 2 2 2004 Strostitute for form 1449A/PTO Complete if Known (Modified) 10/804,762 Application Number ORMATION DISCLOSURE March 19, 2004 Filing Date STATEMENT BY APPLICANT QI, Yan First Named Inventor Art Unit To Be Assigned (use as many sheets as necessary) **Examiner Name** To Be Assigned Sheet 1 1 Attorney Docket Number A-72186/TAL/DCF (471702-00005) of

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
_	A1	5,242,687	09-07-1993	Tykocinski et al.	
	A2	5,601,828	02-11-1997	Tykocinski et al.	
	A3	5,623,056	04-22-1997	Tykocinski et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁶
	B1	WO 02/102852 A2/A3	12-27-2002	Avidex Ltd.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	FINK, P., et al., "Haplotype-specific suppression of cytotoxic T cell induction by antigen inappropriately presented on T cells," <i>J. Exp. Med.</i> _157(1):141-154 (Jan. 1983).	
	C2	HAMBOR, J., et al., "CD8 functions as an inhibitory ligand in mediating the immunoregulatory activity of CD8+cells," J. Immunol. 145(6):1646-1652 (Sep. 1990).	
	СЗ	HAMBOR, J., et al., "Regulation of allogeneic responses by expression of CD8 α-chain of stimulator cells," <i>Int. Immunol.</i> 2(9):8856-8879 (1990).	
	C4	HEEGER, P.S., et al., "T-cell allorecognition and transplant rejection: a summary and update," <i>Am. J. Transplant</i> . 3(5):525-533 (May 2003).	
	C5	KAPLAN, D., et al., "An immunoregulatory function for the CD8 molecule," <i>Proc. Natl. Acad. Sci. USA</i> 86(21):8512-8515 (Nov. 1989).	
	C6	KRIEGER, N., et al., "CD4+ but not CD8+ cells are essential for allorejection," J. Exp. Med. 184(5):2013-2018 (Nov. 1996).	
	C7	QI, Y., et al., "Hybrid antibody mediated veto of cytotoxic T lymphocyte response," <i>J. Exp. Med.</i> 183(5):1973-1980 (May 1996).	
	C8	RAMMENSEE, H., et al., "Class I restricted interaction between suppressor and cytolytic cells in the response to minor histocompatibility antigens," <i>J. Immunol.</i> 132(2):668-672 (Feb. 1984).	
	C9	RAMMENSEE, H., et al., "Suppression of cell-mediated lymphocytoxicity against minor histocompatibility antigens mediated by Lyt-1+ and Lyt-2+ T cells of stimulator strain origin," <i>Eur. J. Immunol.</i> 12(11):930-934 (Nov. 1982).	
	C10	SAMBHARA, S., et al., "Programmed cell death of Te cells signaled by the T cell receptor and the α-3 domain if class I MHC," <i>Science</i> 252(5011):1424-1427 (Jun. 1991).	-
	C11	STAERZ, U., et al., "Treatment of an autoimmune disease with 'classical' T cell veto: a proposal," <i>J. Clin. Immunol.</i> 19(4):195-202 (Jul. 1999).	

Examiner	Date	
Signature	Considered	·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{&#}x27;Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.
This collection of information is required by 37 CEP 1.97 and 1.98. The information is required to obtain or retain a henefit by the public which is to file (and by the